Evening Blue-Light Blocking Glasses ProtocolCircadian Phase Shifting and Melanopic Daylight Filtering DensityThe widespread integration of light-emitting diodes (LEDs) in digital screens and modern indoor environments has resulted in a ubiquitous evening exposure to short-wavelength visible light (with a peak typically between 450 and 470 nm). As established in the photobiology literature, this artificial illumination falsely signals the suprachiasmatic nucleus that it is still daytime, precipitating an acute and profound suppression of endogenous melatonin secretion from the pineal gland1. The clinical manifestation of this physiological error is a delayed circadian phase, prolonged sleep onset latency (SOL), an increase in wake after sleep onset (WASO), and an overall reduction in sleep efficiency and architecture16. To counteract this pervasive modern environmental hazard, blue-light blocking glasses (BBGs) have been widely adopted as a non-pharmacological behavioral intervention. The fundamental premise is the creation of "virtual darkness," strategically filtering short wavelengths to prevent the activation of retinal melanopsin while maintaining sufficient visual acuity to allow individuals to perform normal evening tasks16. However, a rigorous review of clinical meta-analyses reveals significant heterogeneity in the proven efficacy of BBGs, largely due to extreme variations in lens transmission properties and consumer deception. The metric of Melanopic Daylight Filtering Density (mDFD) is utilized by researchers to quantify the true clinical effectiveness of a lens16. Many commercial lenses marketed as "blue blockers" are entirely clear, filtering only negligible fractions of short-wavelength light (often blocking only UV or marginal blue light up to 410-420nm) and failing to achieve an mDFD ≥116. Consequently, these clear lenses provide virtually no protection to the circadian system and fail to prevent melatonin suppression16. For legitimate circadian intervention, the lenses must actively block light up to 500-550 nm, physically necessitating a deep amber or red tint. When proper high-mDFD amber or red lenses are utilized one to two hours prior to a habitual bedtime, patients—particularly those with insomnia, delayed sleep phase syndrome, or pre-sleep anxiety—exhibit significant improvements in subjective sleep quality and reductions in hyperarousal17. Statistical meta-analyses evaluating the efficacy of these evening interventions reveal a distinct divergence between subjective and objective metrics. Data indicates a notable difference in outcomes: subjective sleep quality, as measured by the Pittsburgh Sleep Quality Index (PSQI), shows a large magnitude improvement with a Hedge's g effect size of 1.2517. Similarly, self-reported Total Sleep Time yields a medium effect size of 0.5117. Conversely, objective actigraphy-measured outcomes reveal much more modest, small-to-medium improvements, with objective Total Sleep Time showing a Hedge's g of 0.32 and objective Sleep Efficiency at 0.3117. This statistical disparity highlights that while the psychological and subjective perception of sleep dramatically improves, the objective physiological changes are smaller, suggesting that BBGs are most clinically efficacious for individuals with existing circadian vulnerabilities rather than fully healthy adults16.